Oppelt Melanie, Baumann Michael, Bergmann Ralf, Beyreuther Elke, Brüchner Kerstin, Hartmann Josefin, Karsch Leonhard, Krause Mechthild, Laschinsky Lydia, Leßmann Elisabeth, Nicolai Maria, Reuter Maria, Richter Christian, Sävert Alexander, Schnell Michael, Schürer Michael, Woithe Julia, Kaluza Malte, Pawelke Jörg
OncoRay - National Center for Radiation Research in Oncology, Technische Universität Dresden, Dresden, Germany,
Radiat Environ Biophys. 2015 May;54(2):155-66. doi: 10.1007/s00411-014-0582-1. Epub 2015 Jan 20.
The long-term goal to integrate laser-based particle accelerators into radiotherapy clinics not only requires technological development of high-intensity lasers and new techniques for beam detection and dose delivery, but also characterization of the biological consequences of this new particle beam quality, i.e. ultra-short, ultra-intense pulses. In the present work, we describe successful in vivo experiments with laser-driven electron pulses by utilization of a small tumour model on the mouse ear for the human squamous cell carcinoma model FaDu. The already established in vitro irradiation technology at the laser system JETI was further enhanced for 3D tumour irradiation in vivo in terms of beam transport, beam monitoring, dose delivery and dosimetry in order to precisely apply a prescribed dose to each tumour in full-scale radiobiological experiments. Tumour growth delay was determined after irradiation with doses of 3 and 6 Gy by laser-accelerated electrons. Reference irradiation was performed with continuous electron beams at a clinical linear accelerator in order to both validate the dedicated dosimetry employed for laser-accelerated JETI electrons and above all review the biological results. No significant difference in radiation-induced tumour growth delay was revealed for the two investigated electron beams. These data provide evidence that the ultra-high dose rate generated by laser acceleration does not impact the biological effectiveness of the particles.
将基于激光的粒子加速器集成到放射治疗临床中的长期目标，不仅需要高强度激光的技术发展以及束流检测和剂量输送的新技术，还需要表征这种新的粒子束质量（即超短、超强脉冲）所带来的生物学后果。在本工作中，我们描述了利用小鼠耳部的小型肿瘤模型针对人鳞状细胞癌模型FaDu进行的激光驱动电子脉冲的成功体内实验。为了在全面的放射生物学实验中精确地向每个肿瘤施加规定剂量，在激光系统JETI已有的体外照射技术在束流传输、束流监测、剂量输送和剂量测定方面进一步增强，以用于体内三维肿瘤照射。在用激光加速电子以3 Gy和6 Gy的剂量照射后，测定肿瘤生长延迟。在临床直线加速器上用连续电子束进行参考照射，以便既验证用于激光加速的JETI电子的专用剂量测定，最重要的是审查生物学结果。对于所研究的两种电子束，未发现辐射诱导的肿瘤生长延迟有显著差异。这些数据证明，激光加速产生的超高剂量率不会影响粒子的生物学有效性。
